TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26033094

Group type: EXPERIMENTAL
Intervention: Bedside Paediatric Early Warning System (BedsidePEWS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no severity of illness score)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BedsidePEWS
Number of subjects: 0
Study: 23811617

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided steroid injection (40 mg of methylprednisolone)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Blind steroid injection (40 mg of methylprednisolone)
Number of subjects: 46
Study: 21753226

Group type: EXPERIMENTAL
Intervention: dilute diesel exhaust
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: pure carbon nanoparticulate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: filtered diesel exhaust
Number of subjects: 16

Group type: COMPARATOR
Intervention: filtered air
Number of subjects: 16
Study: 19164401

Group type: EXPERIMENTAL
Intervention: Motor imagery during stretches (n = 6)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Progressive muscle relaxation during stretches (n = 5)
Number of subjects: 11
Study: 17086095

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN), 60 mg orally, once daily for 11 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 14979844

Group type: EXPERIMENTAL
Intervention: Demonstration health promotion projects (n = 728)
Number of subjects: 1955

Group type: COMPARATOR
Intervention: Control group (n = 1,227)
Number of subjects: 1955
Study: 11729017

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9159453

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (IGF-I)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor binding protein 1 (IGFBP-1)
Number of subjects: 27
Study: 7970429

Group type: EXPERIMENTAL
Intervention: Two blood sample method
Number of subjects: 133

Group type: COMPARATOR
Intervention: One blood sample method
Number of subjects: 133
Study: 2444937

Group type: EXPERIMENTAL
Intervention: Unidirectional transvenous shocks (Group A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bidirectional transvenous shocks (Group B)
Number of subjects: 33
Study: 31616139

Group type: EXPERIMENTAL
Intervention: Fortasyn Connect (daily medical food containing docosahexaenoic acid, eicosapentaenoic acid, uridine monophosphate, choline, phospholipids, selenium, folic acid, vitamins B12, B6, C, and E)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fortasyn Connect
Number of subjects: 0
Study: 29045325

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR) 25%
Number of subjects: 218

Group type: COMPARATOR
Intervention: Ad libitum (AL) control
Number of subjects: 218
Study: 26112273

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (TFP) 12.5 μg/h
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-steroid anti-inflammatory drugs (NSAID)
Number of subjects: 52
Study: 24108510

Group type: EXPERIMENTAL
Intervention: Simvastatin (60 mg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 21784525

Group type: EXPERIMENTAL
Intervention: Flutter Valve
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (normal ventilation in pressure controlled mode)
Number of subjects: 20
Study: 19653757

Group type: EXPERIMENTAL
Intervention: Informative spatial cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reflexive activation of location-sensitive neurons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory spatial cues
Number of subjects: 0
Study: 16463435

Group type: EXPERIMENTAL
Intervention: etanercept/etanercept
Number of subjects: 141

Group type: COMPARATOR
Intervention: placebo/etanercept
Number of subjects: 141
Study: 12771841

Group type: EXPERIMENTAL
Intervention: Endoscopic decompression
Number of subjects: 38

Group type: COMPARATOR
Intervention: Open decompression
Number of subjects: 38
Study: 11016522

Group type: EXPERIMENTAL
Intervention: Modified assertive community treatment
Number of subjects: 312

Group type: COMPARATOR
Intervention: Standard treatment in community mental health centres
Number of subjects: 312
Study: 9686071

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (IBPB) alone
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (IBPB) with sedation (midazolam: 1‐3 mg)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (IBPB) with general anaesthesia (patient's request)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (IBPB) with general anaesthesia (due to IBPB failure)
Number of subjects: 167
Study: 8452378

Group type: EXPERIMENTAL
Intervention: Flavoured UHT cow's milk drink
Number of subjects: 169

Group type: COMPARATOR
Intervention: Flavoured UHT soy milk drink (placebo)
Number of subjects: 169
Study: 2943191

Group type: EXPERIMENTAL
Intervention: Midazolam 0.07 mg/kg intramuscularly
Number of subjects: 96

Group type: COMPARATOR
Intervention: Matching placebo (midazolam vehicle)
Number of subjects: 96
Study: 29084094

Group type: EXPERIMENTAL
Intervention: LO + BFR group
Number of subjects: 25

Group type: COMPARATOR
Intervention: HI group
Number of subjects: 25

Group type: COMPARATOR
Intervention: LO group
Number of subjects: 25
Study: 29145215

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26303694

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery (HALS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional laparoscopic surgery (TLS)
Number of subjects: 60
Study: 23064733

Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Program (CSEP)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Traditional Exercise Program (TEP)
Number of subjects: 340
Study: 21451458

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19483355

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 100
Study: 16792771

Group type: EXPERIMENTAL
Intervention: Topical application of salicylic acid (twice daily then once daily)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control lesions (not treated with salicylic acid)
Number of subjects: 5
Study: 15119640

Group type: EXPERIMENTAL
Intervention: Graduate-measured volume using a 2-L graduated cylinder
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Weighed volume, with and without bag weight, using a digital floor scale or spring scale
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cycler-measured volume using the initial drain and ultrafiltration indicated by the cycler, plus the prescribed inflow volume without the last fill
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Weight of the drained bags (for CAPD)
Number of subjects: 28
Study: 11829239

Group type: EXPERIMENTAL
Intervention: Sterile gloves
Number of subjects: 609

Group type: COMPARATOR
Intervention: Clean gloves
Number of subjects: 609
Study: 9517371

Group type: EXPERIMENTAL
Intervention: bisoprolol (5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: nadolol (40 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 7527104

Group type: EXPERIMENTAL
Intervention: Trandolapril 0.5 mg
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Trandolapril 1 mg
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 2685740

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO) therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional medical therapy (CMT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Overall survival of ECMO-treated infants
Number of subjects: 39

Group type: COMPARATOR
Intervention: Overall survival of CMT-treated infants
Number of subjects: 39
Study: 1178099

Group type: EXPERIMENTAL
Intervention: Holter shunts
Number of subjects: 260

Group type: COMPARATOR
Intervention: Pudenz shunts
Number of subjects: 260
Study: 29111629

Group type: EXPERIMENTAL
Intervention: Muay Thai training twice a week (G2X)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Muay Thai training three times a week (G3X)
Number of subjects: 20
Study: 26911725

Group type: EXPERIMENTAL
Intervention: Viewing a male vignette
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Viewing a female vignette
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Male participants studying non-relevant degrees viewing a male vignette
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Students studying clinically non-relevant degrees
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Overall MHFA scores
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Provision of support and information
Number of subjects: 483
Study: 25803949

Group type: EXPERIMENTAL
Intervention: Peer Support Worker (PSW)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mental Health Worker (MHW)
Number of subjects: 15
Study: 22936289

Group type: EXPERIMENTAL
Intervention: Paced respiration intervention
Number of subjects: 218

Group type: COMPARATOR
Intervention: Fast shallow breathing control
Number of subjects: 218

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 218
Study: 20844186

Group type: EXPERIMENTAL
Intervention: Increased leucine concentration (LEU; 3.5 g leucine)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (CTRL; 1.8 g leucine)
Number of subjects: 14
Study: 19080342

Group type: EXPERIMENTAL
Intervention: Laser Epithelial Keratomileusis (LASEK)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Photorefractive Keratectomy (PRK)
Number of subjects: 604
Study: 16844491

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination with controlled ovarian hyperstimulation for 6 months
Number of subjects: 253

Group type: COMPARATOR
Intervention: Expectant management for 6 months
Number of subjects: 253
Study: 12703999

Group type: EXPERIMENTAL
Intervention: PG regimen (cisplatin and gemcitabine)
Number of subjects: 64

Group type: COMPARATOR
Intervention: PN regimen (cisplatin and vinorelbine)
Number of subjects: 64
Study: 10954006

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 964

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 964
Study: 9368834

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) treatment
Number of subjects: 12
Study: 1541712

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 27
Study: 3890465

Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 27
Study: 29799676

Group type: EXPERIMENTAL
Intervention: Rucaparib 40-500 mg QD
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rucaparib 240-840 mg BID
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg BID (phase 2)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Rucaparib 40 mg (single dose)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Rucaparib 300 mg (single dose)
Number of subjects: 72
Study: 29120980

Group type: EXPERIMENTAL
Intervention: Cold-Water Immersion (CWI) for 20 minutes at 5-10° C
Number of subjects: 11

Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 11
Study: 27936084

Group type: EXPERIMENTAL
Intervention: Endurance training (END) for 3 weeks (4 days/week) at ∼65% VO2peak work rate (30 minutes)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sprint interval training (SIT) for 3 weeks (4 days/week) with eight 20-second intervals at ∼170% VO2peak WR separated by 10 seconds of active rest
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both END and SIT
Number of subjects: 21
Study: 25607702

Group type: EXPERIMENTAL
Intervention: ALA-PDT (2 treatments)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ALA-PDT (1 treatment) + ingenol mebutate 0.015% gel (3 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: ingenol mebutate 0.015% gel alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ALA-PDT (1 treatment) + ingenol mebutate gel (3 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: ingenol mebutate gel alone
Number of subjects: 24
Study: 23826844

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 3709

Group type: COMPARATOR
Intervention: ER tolterodine 4 mg
Number of subjects: 3709

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3709
Study: 20642044

Group type: EXPERIMENTAL
Intervention: Soft ice
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Iced water
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ice gel
Number of subjects: 32
Study: 18521900

Group type: EXPERIMENTAL
Intervention: Selective leukocytapheresis (5 sessions, once weekly)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unchanged maintenance treatment (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Selective leukocytapheresis
Number of subjects: 60
Study: 15713151

Group type: EXPERIMENTAL
Intervention: Triple tourniquets
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 12799510

Group type: EXPERIMENTAL
Intervention: PCV-9
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control vaccine (conjugate meningococcus C vaccine)
Number of subjects: 262
Study: 11059992

Group type: EXPERIMENTAL
Intervention: Risperidone (single dose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Risperidone (six weeks treatment)
Number of subjects: 8
Study: 8609218

Group type: EXPERIMENTAL
Intervention: Basal fasting portal vein insulinemia-hypoglucagonemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal portal vein insulinemia-basal glucagonemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basal peripheral insulinemia-hypoglucagonemia
Number of subjects: 0
Study: 1616162

Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Atropine (0.02 mg/kg)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Meperidine (1.5 mg/kg)
Number of subjects: 154
Study: 3745103

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg, sublingual administration)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 29067841

Group type: EXPERIMENTAL
Intervention: Central obesity (WC > 80 cm for women and > 85 cm for men)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MS) criteria
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Being male
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Married/cohabit
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Longer working hours
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Eating less vegetables
Number of subjects: 737
Study: 26679060

Group type: EXPERIMENTAL
Intervention: Active HFrTMS (10 Hz, 100% motor threshold)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 17
Study: 24879495

Group type: COMPARATOR
Intervention: THC 29 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: THC 49 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: THC 69 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23039319

Group type: EXPERIMENTAL
Intervention: High-dose amoxicillin/clavulanic acid (80 mg/kg/day for 10 days)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Cefdinir (14 mg/kg/day for 5 days)
Number of subjects: 330
Study: 20657877

Group type: EXPERIMENTAL
Intervention: Resorbable collagen barriers supported by osteosynthesis plates
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonresorbable titanium‐reinforced expanded polytetrafluoroethylene barriers
Number of subjects: 22
Study: 18320518

Group type: EXPERIMENTAL
Intervention: Peripheral retinal scatter photocoagulation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Untreated (natural course disease)
Number of subjects: 101
Study: 15994038

Group type: EXPERIMENTAL
Intervention: Tribulus terrestris extract (20 mg/kg body weight per day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tribulus terrestris extract (10 mg/kg body weight per day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 21
Study: 12538203

Group type: COMPARATOR
Intervention: Control (no risk or pain)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Pain (pain but no risk)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Risk (risk but no pain)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Understanding risk or pain (all groups)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Understanding risk or pain (participants who understood)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Participants agreeing to participate without understanding risks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Feeling pressured to participate
Number of subjects: 150
Study: 10434219

Group type: EXPERIMENTAL
Intervention: Propofol-N2O group
Number of subjects: 69

Group type: COMPARATOR
Intervention: Propofol alone group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study: 7876773

Group type: EXPERIMENTAL
Intervention: Attention shifts to one's name
Number of subjects: 34
Study: 2131860

Group type: EXPERIMENTAL
Intervention: Group 1: Lungs collapsed (0/0)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 2: Static inflation with +5 cm H2O and F1O2 1.0 (+5/1.0)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 3: Static inflation with +5 cm H2O and F1O2 0.21 (+5/0.21)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 4: Static inflation with +15 cm H2O and F1O2 1.0 (+15/1.0)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 5: Static inflation with +15 cm H2O and F1O2 0.21 (+15/0.21)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 6: Controlled mechanical ventilation (PEEP +5 cm H2O; F1O2 1.0)
Number of subjects: 90
Study: 142579

Group type: EXPERIMENTAL
Intervention: Streptozotocin plus 5-fluorouracil
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Streptozotocin plus cyclophosphamide
Number of subjects: 116
Study: 31146548

Group type: EXPERIMENTAL
Intervention: Home-based HIV self-testing (HST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinic-based testing
Number of subjects: 0
Study: 31463821

Group type: EXPERIMENTAL
Intervention: Sublingual SAM 10 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Oral SAM 10 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intravenous SAM
Number of subjects: 55

Group type: COMPARATOR
Intervention: Oral SAM 10 mg under fed conditions (cohort 1)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Oral SAM 10 mg for young and elderly participants
Number of subjects: 55
Study: 28113118

Group type: EXPERIMENTAL
Intervention: Opioid use partnerships (sexual/romantic partnerships)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Racially concordant partnerships reported by white study participants
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Racially discordant partnerships reported by African American study participants
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Partnerships where either member witnessed the other experience an overdose
Number of subjects: 134
Study: 25195970

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 1499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1499
Study: 23741995

Group type: EXPERIMENTAL
Intervention: Sandblasting + Er:YAG laser irradiated
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sandblasting
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiated + liner applied
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sandblasting + Nd:YAG laser irradiated
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nd:YAG laser irradiated + liner applied
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sandblasted + liner applied
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sandblasted + Nd:YAG laser irradiated
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiated
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sandblasted + Er:YAG laser irradiated
Number of subjects: 200
Study: 21536404

Group type: EXPERIMENTAL
Intervention: ePTFE/Gore grafts
Number of subjects: 99

Group type: COMPARATOR
Intervention: polyester/Braun grafts
Number of subjects: 99

Group type: COMPARATOR
Intervention: polyester/Vascutek grafts
Number of subjects: 99
Study: 18562974

Group type: EXPERIMENTAL
Intervention: Intensive interventions targeting walking behavior
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Brief telephone prompts
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Prescriptions to walk 5-7 days/week
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Prescriptions to walk at moderate intensity
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mediated interventions delivering physical activity promotion materials through non-face-to-face channels
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mass media campaigns targeting broader audiences
Number of subjects: 14
Study: 16413652

Group type: EXPERIMENTAL
Intervention: Continuous augmented feedback
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intermittent (66% of the time) augmented feedback
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 36
Study: 14499422

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (10 mg to 40 mg q12h)
Number of subjects: 36
Study: 11273538

Group type: EXPERIMENTAL
Intervention: antacid-acid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: acid-antacid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: acid-acid
Number of subjects: 12

Group type: COMPARATOR
Intervention: antacid-antacid (control)
Number of subjects: 12
Study: 9089851

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg of nalbuphine intravenously
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.0, 0.3, 0.6, 0.9, 1.2, and 1.5 mg/kg of 2‐chloroprocaine
Number of subjects: 31